Epofolate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Epofolate
Accession Number
DB12266
Type
Small Molecule
Groups
Investigational
Description

Epofolate has been used in trials studying the treatment of Advanced Solid Tumors.

Synonyms
  • BMS-753493
Categories
UNII
Q3XAW4B1DP
CAS number
958646-17-8
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Epofolate.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Epofolate.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Epofolate.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Epofolate.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Epofolate.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Epofolate.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Epofolate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Epofolate.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Epofolate.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Epofolate.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epofolate.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Epofolate.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Epofolate.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Epofolate.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Epofolate.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Epofolate.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Epofolate.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Epofolate.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Epofolate.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Epofolate.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911308

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2TerminatedTreatmentAdvanced Solid Tumors2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 20, 2016 15:46 / Updated on November 06, 2017 06:46